Stock 3692 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hansoh Pharmaceutical Group Company Limited

Equities

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
17.22 HKD +2.50% Intraday chart for Hansoh Pharmaceutical Group Company Limited +11.96% +9.26%
Apr. 03 Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug MT
Apr. 03 Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 133,984 187,313 91,686 77,600 94,413 94,413 -
Enterprise Value (EV) 1 122,171 173,688 76,984 59,985 84,854 72,936 71,103
P/E ratio 51.7 x 71.9 x 35.2 x 29.8 x 26 x 24.8 x 25 x
Yield - 0.21% 0.47% 0.76% 0.68% 0.98% 1%
Capitalization / Revenue 15.4 x 21.6 x 9.23 x 8.27 x 8.4 x 7.99 x 7.58 x
EV / Revenue 14.1 x 20 x 7.75 x 6.39 x 8.4 x 6.17 x 5.71 x
EV / EBITDA 40.9 x 57.7 x 24.2 x 19.9 x 27.4 x 17.3 x 16.7 x
EV / FCF 44.5 x 180 x 36.6 x 24.3 x 22.1 x 20.6 x 18.2 x
FCF Yield 2.25% 0.55% 2.73% 4.12% 4.52% 4.85% 5.5%
Price to Book 10.3 x 10.5 x 4.58 x 3.43 x 3.77 x 3.3 x 3 x
Nbr of stocks (in thousands) 5,788,611 5,918,991 5,922,350 5,920,764 5,923,035 5,923,035 -
Reference price 2 23.15 31.65 15.48 13.11 15.94 15.94 15.94
Announcement Date 3/30/20 3/30/21 3/29/22 3/27/23 3/26/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 8,683 8,690 9,935 9,382 10,104 11,814 12,461
EBITDA 1 2,990 3,008 3,175 3,019 3,101 4,211 4,270
EBIT 1 2,788 2,775 2,897 2,674 2,735 3,824 3,862
Operating Margin 32.11% 31.93% 29.16% 28.5% 27.07% 32.37% 30.99%
Earnings before Tax (EBT) 1 3,001 3,098 3,300 2,948 3,766 4,325 4,428
Net income 1 2,557 2,569 2,713 2,584 3,278 3,742 3,753
Net margin 29.45% 29.56% 27.31% 27.54% 32.44% 31.68% 30.12%
EPS 2 0.4481 0.4400 0.4400 0.4400 0.5500 0.6427 0.6375
Free Cash Flow 1 2,748 962.8 2,102 2,470 3,482 3,539 3,912
FCF margin 31.65% 11.08% 21.16% 26.33% 34.63% 29.95% 31.39%
FCF Conversion (EBITDA) 91.91% 32.01% 66.2% 81.83% 102.77% 84.03% 91.61%
FCF Conversion (Net income) 107.49% 37.48% 77.48% 95.62% 126.14% 94.56% 104.24%
Dividend per Share 2 - 0.0651 0.0732 0.1000 0.1082 0.1557 0.1594
Announcement Date 3/30/20 3/30/21 3/29/22 3/27/23 3/26/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S1 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 4,599 4,083 3,980 4,711 4,402 5,534 4,434 4,948 4,511 5,593 6,161 5,679 5,309 6,434
EBITDA - - - - - - - - - - - - - -
EBIT 1 - - - - 1,337 1,560 1,322 1,353 1,047 1,688 2,189 1,272 1,459 1,041
Operating Margin - - - - 30.38% 28.19% 29.8% 27.34% 23.2% 30.19% 35.54% 22.41% 27.48% 16.19%
Earnings before Tax (EBT) - - - - - - - - - - - - - -
Net income - - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - -
EPS - - - - - - - 0.2200 - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 8/30/19 3/30/20 9/17/20 3/30/21 8/26/21 3/29/22 8/26/22 3/27/23 9/28/23 3/26/24 - - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - -
Net Cash position 1 11,812 13,625 14,702 17,615 17,311 21,478 23,311
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 2,748 963 2,102 2,470 3,482 3,539 3,912
ROE (net income / shareholders' equity) 33% 16.6% 14.3% 12.1% 11.4% 13.5% 12.5%
ROA (Net income/ Total Assets) 18.3% 12.7% 11.3% 9.04% 8.93% 11% 10.7%
Assets 1 14,002 20,184 23,976 28,581 30,916 34,109 35,186
Book Value Per Share 2 2.250 3.020 3.380 3.820 4.220 4.820 5.300
Cash Flow per Share 2 0.6100 0.4100 0.4300 0.4600 0.4900 0.6600 0.6500
Capex 1 581 1,428 460 271 398 478 463
Capex / Sales 6.7% 16.43% 4.63% 2.89% 3.96% 4.04% 3.72%
Announcement Date 3/30/20 3/30/21 3/29/22 3/27/23 3/26/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hansoh Pharmaceutical Group Company Limited

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
15.94 CNY
Average target price
17.47 CNY
Spread / Average Target
+9.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED Stock Hansoh Pharmaceutical Group Company Limited
+9.26% 13.03B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 3692 Stock
  4. Financials Hansoh Pharmaceutical Group Company Limited